Published in final edited form as:

Biochem Pharmacol. 2007 April 15; 73(8): 1135–1145.

Regulation of α_2 AR trafficking and signaling by interacting proteins

Qin Wang[¥] and Lee E. Limbird[§]

[¥]*Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL35294*

[§]*Department of Biomedical Sciences, Meharry Medical College, Nashville, TN 37208*

Abstract

The continuing discovery of new G protein-coupled receptor (GPCR) interacting proteins and clarification of the functional consequences of these interactions has revealed multiple roles for these events. Some of these interactions serve to scaffold GPCRs to particular cellular micro-compartments or to tether them to defined signaling molecules, while other GPCR-protein interactions control GPCR trafficking and the kinetics of GPCR-mediated signaling transduction. This review provides a general overview of the variety of GPCR-protein interactions reported to date, and then focuses on one prototypical GPCR, the α_2 AR, and the *in vitro* and *in vivo* significance of its reciprocal interactions with arrestin and spinophilin.

It seems appropriate to recognize the life and career of Arthur Hancock with a summary of studies that both affirm and surprise our preconceived notions of how nature is designed, as his career-long efforts similarly affirmed the complexity of human biology and attempted to surprise pathological changes in that biology with novel, discovery-based therapeutic interventions. Dr Hancock's love of life, of family, and of commitment to making the world a better place are a model of the life well lived, and truly missed by those who were privileged to know, and thus love, him.

Keywords

α_2 -adrenergic receptor; protein-protein interaction; arrestin; spinophilin; G protein-coupled receptor kinase; 14-3-3 ζ

1. Introduction

The α_2 adrenergic receptor (AR) belongs to the G protein-coupled receptor (GPCR) superfamily. *In vivo*, activation of the α_2 AR by endogenous ligand, epinephrine and norepinephrine, leads to decrease in epileptogenesis [1] and anxiety [2]. In response to α_2 -agonists, the α_2 AR activation can lower blood pressure by central mechanisms [3;4], evoke sedation [5], reduce pain perception [5;6], and improve working memory [7–9]. There are three subtypes of α_2 ARs, α_{2A} -, α_{2B} - and α_{2A} AR, which are encoded by three different genes but all couple to the $G_{i/o}$ subfamily of G proteins to inhibit adenylyl cyclase and voltage-gated Ca^{2+}

Correspondence should be addressed to: 1. Qin Wang, MD, PhD, Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL 35294. Tel.: 205-996-5099; Fax: 205-975-9028; E-mail: qinwang@uab.edu; 2. Lee E. Limbird, PhD, Department of Biomedical Sciences, Meharry Medical College, Nashville, TN 37208. Tel.: 615-327-6063; fax:615-627-6144; E-mail: llimbird@mmc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

channels and to activate receptor-operated K^+ channels and mitogen-activated protein kinase (MAPK) in native cells [10–12].

Discovery of regulatory of G protein signaling (RGS) proteins a decade ago has changed the historic view of GPCR signaling as simplistic coupling of receptors to G proteins to effectors. Additionally, protein-protein interactions are now appreciated as a critical means to fine tune GPCR functions. GPCR-interacting proteins can regulate both receptor trafficking and receptor-mediated signaling. The α_2 AR has been identified to interact with a number of proteins, including GPCRs, kinases and scaffolding proteins such as 14-3-3 ζ , arrestin and spinophilin (see Table 1). Interactions of the α_2 AR with some of these proteins have been implicated in controlling α_2 AR surface retention, internalization, signaling desensitization, response sensitivity as well as scaffolding α_2 AR-mediated intracellular signaling. In this review, we focus on α_2 AR interaction with scaffolding proteins and the functions these proteins play in regulating α_2 AR trafficking and signaling.

2. Proteins interacting with the α_2 AR

2.1. GPCRs

Accumulating evidence indicates that homo- and heterodimerization (or oligomerization) of GPCRs exist *in vivo* and may represent an important mechanism for complex GPCR functions [13;14]. The α_{2A} AR has been reported to form homodimers [15;16] as well as to interact with some other GPCRs to form heterodimers. Compared to the α_{2A} AR homodimerization, heterodimerization of the α_{2A} AR subtype with the α_{2C} AR subtype significantly attenuates agonist-induced phosphorylation of the α_{2A} AR subtype, leading to a reduction of arrestin binding as well as arrestin-mediated Akt activation by α_2 -agonist [16]. Heterodimerization of α_{2A} AR and β_1 AR in HEK cells significantly alters ligand binding properties of the β_1 AR but that of not the α_{2A} AR, and leads to internalization of β_1 AR in response to α_2 -agonists [17]. On the other hand, heterodimerization of α_{2C} AR with β_2 AR notably reduces the intracellular pool of α_{2C} AR in HEK cells, and such increased α_{2C} AR surface expression results in enhanced α_{2C} AR internalization and ERK activation in response to α_2 -agonist stimulation [18].

Adrenergic-opioid synergism in induction of spinal analgesia has long been noted [6]. Interactions of the α_{2A} AR with the mu [19;20] and delta [21] opioid receptors (OR) have been observed in both heterologous cells and neurons. In cells coexpressing MOR with the α_{2A} AR, morphine (MOR agonist) treatment led to a significant higher level of GTP γ S binding and ERK activation than in cells expressing MOR alone [19]. Coexpression of α_{2A} AR with DOR also enhanced DOR-mediated neurite outgrowth [21]. These data suggest that physical interaction between opioid receptors and the α_{2A} AR leads to functional interaction between these receptors at the cellular level [19;21]. Intriguingly, simultaneous stimulation with a combination of opioids and α_2 -agonists caused a decrease of MOR- α_{2A} AR interaction as well as a remarkable reduction of MOR-mediated signaling in cells coexpressing these two receptors [19]. Also, hetero-oligomers of α_{2A} AR and MOR did not lead to transactivation of G proteins or interdependent redistribution on one another following agonist treatment [20]. Taken together, while physical interaction between α_{2A} AR and MOR represents a potential molecular mechanism contributing to the observed adrenergic-opioid synergism, additional complex mechanisms likely underlie functional cross-talk of adrenergic-opioid system *in vivo*.

2.2. Kinases

Like most GPCRs, the α_2 AR is substrate of G protein-coupled receptor kinases (GRKs). The GRKs represent a family of seven members with serine threonine kinase activity. GRKs 1 and 7 phosphorylate rhodopsin and iodopsin, respectively, in the visual system. GRK4 is mainly

expressed in testes. GRKs 2, 3, 5 and 6 are ubiquitously expressed and regulate most GPCRs [22;23]. Through interaction of its C-terminus with G protein $\beta\gamma$ subunits, GRK translocates to plasma membrane [24] and specifically phosphorylates agonist-occupied or conformationally activated GPCRs [22;23]. GRK-catalyzed phosphorylation, which leads to subsequent arrestin binding, represents a major mechanism for homologous desensitization of GPCRs [22;23].

GRK2 phosphorylation occurs in both the α_{2A} - and α_{2B} AR subtypes. A tetraserine sequence (S-296–299) in the 3i loop of the α_{2A} AR [25] and non-contiguously distributed serines in the 3i loop of the α_{2B} AR subtype [26] have been identified as GRK phosphorylation sites. By contrast, the α_{2C} AR subtype does not appear to be a substrate for GRK-catalyzed phosphorylation, even though its 3i loop contains multiple serine and threonine residues organized in a putative GRK favored motif [27]. The fact that the α_{2A} AR bearing an α_{2C} AR 3i loop but not the α_{2C} AR bearing an α_{2A} AR 3i loop gets phosphorylated upon agonist stimulation suggests that agonist-induced conformational change of the receptor backbone determines the level of α_2 AR phosphorylation by GRK [27].

Direct interaction of the α_{2A} AR with GRK2 involves the 2 and 3 intracellular (2i and 3i) loops but not the 1i loop or the C-tail of the α_{2A} AR [28]. Within the α_{2A} AR 3i loop, several basic residues at the membrane proximal N- and C-terminal regions as well as in a region adjacent to the phosphorylation sites mediate association with GRK2 [28].

The α_{2A} AR also can be phosphorylated by PKC [29;30] at residues located at the N- and C-terminal regions of the 3i loop [30–32]. Phosphorylation of α_{2A} AR by PKC can cause heterologous desensitization of the α_{2A} AR [29], and may also affect constitutive coupling of G proteins [30]. Therefore, PKC phosphorylation may represent a mechanism for crosstalk between α_{2A} AR-mediated and other signaling pathways.

2.3. Proteins interacting with the C-terminus of the α_2 AR

The α_2 AR has a relatively short C-terminal cytoplasmic tail that has been implicated in receptor downregulation [33]. The C-terminal domains of all three α_2 AR subtypes also have been shown to interact with α -subunit of eukaryotic translation initiation factor 2B (eIF-2B) [34] as well as with the amyloid precursor like protein 1 (APLP1) [35], a homologue of the β -amyloid precursor protein (APP) involved in Alzheimer's disease [36]. Coexpression of APLP1 with the α_{2A} AR in HEK cells significantly increases α_{2A} AR-mediated inhibition of adenylyl cyclase activity [35]. The functional relevance of α_2 AR interactions with these proteins in native tissues has not yet been established.

2.4. Scaffolding proteins interacting with the 3i loop of the α_2 AR

In polarized renal epithelial cells, all three subtypes of α_2 AR are primarily localized at the basolateral surface and manifest a surface half life ($t_{1/2}$) of 10–12 hrs [37;38]. In an effort to map sequence regions responsible for α_2 AR targeting and retention at the basolateral surface, Keefer *et al.* found that deletion of the third intracellular loop (3i loop) resulted in a much fast turnover of the α_2 AR on that surface [39;40]. Furthermore, the entire 3i loop seems to be involved in α_{2A} AR basolateral retention, since no single region within the loop can fully account for the accelerated turnover of the $\Delta 3i\alpha_{2A}$ AR [41].

Given its importance in regulating α_2 AR retention, the 3i loop has been used as a ligand to identify intracellular interacting proteins that may contribute to α_2 AR retention at the cell surface. Two scaffolding proteins, 14-3-3 ζ [42] and spinophilin [43], were identified to interact with the 3i loops of all three α_2 AR subtypes by gel overlay analysis and GST pull-down assay.

Interestingly, interaction of the α_2 AR with these two proteins involves multiple, non-contiguous regions of sequence of the 3i loop, concurring with the fact that multiple regions of the 3i loop contribute to α_2 AR surface retention. In addition to 14-3-3 ζ and spinophilin, arrestin also binds to the 3i loop of α_2 AR [44–46]. As discussed below, interaction of the 3i loop with these scaffolding proteins regulates both α_2 AR trafficking and signaling.

3. Regulatory cycle of 14-3-3 ζ , arrestin and spinophilin with the α_2 AR

To understand the functional relevance of interactions of arrestin, 14-3-3 ζ , and spinophilin with the 3i loop of α_2 ARs, we explored whether these proteins share protein-protein interaction domains within the 3i loop of the α_2 AR. Our data demonstrated that: 1) multiple, non-contiguous regions of sequence are needed for interactions of the α_2 AR loop with 14-3-3 ζ , arrestin, and spinophilin, 2) the relative affinity of the *un*phosphorylated 3i loop for interacting proteins is: spinophilin (Sp151–444) $\approx$ arrestin 3 $\gg$ 14-3-3 ζ , 3) arrestin and 14-3-3 ζ interact with regions in the 3i loop that are not involved in coupling to G proteins, but that spinophilin requires both the amphipathic helices at the base of transmembrane (TM) domains 5 and 6 as well as non-contiguous regions of the 3i loop for its interactions with the α_2 AR [46].

One important question was whether or not these interactions occurred independently of one another in different target cells or differing compartments of a given cell, or whether they were part of a regulatory cycle in the context of an individual cell. Fig. 1 suggests a functional relationship among these interactions. Interactions of 14-3-3 ζ are proposed to occur with the α_2 AR in its inactive state. This interpretation derives from the finding that α_2 AR-14-3-3 ζ interactions can be competed for by phosphorylated Raf peptides, but not by corresponding non-phosphorylated peptides [42]. Thus, the α_2 AR appears to interact with 14-3-3 ζ at a site shared by phosphorylated Raf, as initially demonstrated by Muslin [47;48]. Since α_2 AR activation leads to downstream Ras-Raf activation [49], it is reasonable to propose that α_2 AR activation would ultimately disrupt interaction with 14-3-3 ζ due to production of the endogenous competitor, phosphorylated Raf. In contrast to loss of α_2 AR-14-3-3 ζ interactions upon agonist binding to the receptor, agonist activation enhances the binding of both arrestin and spinophilin [43;46] with the α_2 AR. Indeed, spinophilin and arrestin compete for interaction with the α_2 AR [46]. It appears that the selection between α_2 AR binding to arrestin or to spinophilin depends on the phosphorylation state of the receptor. Whereas arrestin binds more effectively to the GRK-phosphorylated receptor, spinophilin favors interactions with the non-phosphorylated receptor [46]. Thus, there is an equilibrium between agonist-receptor-arrestin and agonist-receptor-spinophilin interactions, and this equilibrium can be altered by changes in available concentrations of arrestin *vs.* spinophilin as well as the phosphorylation state of the α_2 AR in the target cell. Spinophilin appears to serve as a functional antagonist of arrestin functions, both those that lead to receptor deactivation and redistribution and those that contribute to receptor activation of signaling [50]. Below, we discuss the functional relevance of α_2 AR interaction with arrestin and spinophilin respectively.

4. Arrestin plays multiple roles in regulating α_2 AR trafficking and signaling

Arrestin is a critical regulator for almost all known GPCRs. Arrestin was first discovered for its role in desensitization (“arresting”) of phototransduction [51]. In response to light, rhodopsin undergoes conformational changes induced by light-evoked electronic changes in its covalently bound ligand, retinol. These changes result in activation of the visual G protein, transducin. In addition to activation of molecular pathways that mediate the visual response, signal activation also results in activation of rhodopsin kinase, phosphorylation of rhodopsin, and stabilization of rhodopsin’s interaction with arrestin (the “48K antigen”) [52–54]. Arrestin

binding to rhodopsin leads to stabilization of rhodopsin's phosphorylated state and to functional uncoupling from transducin, thus terminating activation.

Visual arrestin is a member of a protein family of arrestins [55]. Arrestins 1 (rods) and 4 (cones) are expressed in the visual system. Arrestins 2 (also known as β -arrestin 1) and 3 (β -arrestin 2) are ubiquitously expressed. A role of arrestin has been revealed not only in terminating signaling pathways [56], but also in serving as an adaptor protein bringing these receptors into association with clathrin-coated pits, thus facilitating agonist-evoked GPCR internalization [57;58]. Furthermore, arrestin has been implicated as a scaffold for GPCR interaction with other signaling pathways, such as extracellular signal-regulated kinase (ERK) [59] and c-Jun amino-terminal kinase (JNK) [60] pathways. Thus, arrestin appears to serve as a molecular switch for signal activation as well as deactivation and receptor redistribution.

All three α_2 AR subtypes interact with arrestin 3 [44–46]. The α_{2B} AR also interacts with arrestin 2 with a relatively lower affinity than that with arrestin 3 [45]. Arrestin regulation of α_2 AR functions discussed below are based on studies on α_{2A} - and α_{2B} AR subtypes.

4.1. Arrestin stabilizes α_2 AR phosphorylation

Arrestin enhances agonist-elicited GRK-catalyzed phosphorylation of many GPCRs [61–63]. This also holds true for the α_2 ARs. Overexpression of arrestin 3 in COSM6 cells, which have a relatively low level of endogenous arrestin, greatly increases the level of agonist-induced α_2 AR phosphorylation [50]. Overexpression of arrestin 3 does not affect GRK2 interaction with the receptor [50], indicating that increased phosphorylation of α_2 AR observed with overexpression of arrestin 3 is likely due to stabilization of phosphorylation (i.e. preventing receptor dephosphorylation, as shown previously for the paradigmatic GPCR, rhodopsin [62;64;65]), rather than to enhancement of GRK2 association. Further corroboration of the importance of arrestin in achieving detectable phosphorylation of agonist-occupied α_2 AR is the evidence that in mouse embryonic fibroblasts (MEFs) derived from mice null for both arrestin 2 and arrestin 3 (Arr2,3^{-/-}), agonist-induced phosphorylation of the α_2 AR is more difficult to detect than in MEFs isolated from WT mice expressing arrestin [50].

4.2. Arrestin mediates α_2 AR endocytosis

Arrestin mediates agonist-evoked internalization of a number of GPCRs through clathrin-coated pits by directly interacting with clathrin [57] and AP2 [58]. Although the α_{2A} - and α_{2B} AR exhibit different internalization profiles in response to agonist [66;67], endocytosis of both subtypes requires the presence of arrestin, as revealed by immunofluorescence and cell surface ELISA approaches ([50]; Wang, Brady and Limbird, unpublished data). In WT cells, ~20% of the α_{2A} and ~40% of the α_{2B} AR undergo endocytosis after agonist treatment. However, in MEFs without arrestin expression (Arr2,3^{-/-}), no significant loss of surface α_2 AR following agonist stimulation is detected ([50]; Wang, Brady and Limbird, unpublished data).

Based on their abilities to associate with arrestin post endocytosis, GPCRs are divided into two classes. Endocytosis of so-called class A GPCRs is not accompanied by arrestin co-localization with receptors in an endocytosed compartment and receptor endocytosis is followed by recycling and resensitization [63;68]. On the other hand, following internalization of class B GPCRs, arrestin trafficks with the receptor to intracellular compartments, where subsequent GPCR trafficking to lysosomes leads to receptor degradation and receptor down-regulation [55;63;68]. The α_2 AR appears to be a class A receptor. Thus, arrestin-mediated internalization of the α_2 AR serves as a prelude for receptor recycling. As discussed below, arrestin-mediated endocytosis and subsequent recycling of the α_2 AR may lead to an acceleration of α_2 AR-evoked signaling processes.

4.3. Arrestin regulates spatiotemporal properties of α_2 AR-activated ERK signaling

GPCRs can activate ERK1/2 signaling through G protein-dependent and arrestin-dependent pathways [69]. G protein-dependent activation of ERK occurs transiently and active ERK signal is translocated into nuclei, whereas arrestin-dependent, G protein-independent activation of ERK has a sustained signal and is restricted to the cytosol [69;70]. Our studies have demonstrated that α_2 AAR endogenously expressed in MEFs evokes ERK signaling in a G protein-dependent manner [50;71]. In this process, arrestin seems to be dispensable, since α_2 -agonists are able to evoke ERK activation in arrestin-deficient MEFs with a potency similar to that observed in WT cells [71].

Although not required for α_2 AR-evoked ERK activation *per se*, arrestin tightly regulates the time course of this process. Without arrestin expression, the α_2 AAR-evoked ERK signal is much extended [50;71], consistent with the role of arrestin in desensitization. Deletion of the GRK phosphorylation sites from the α_2 AAR, which decreases the receptor binding affinity for arrestin, also leads to prolonged ERK activation [50]. More intriguingly, the rate of α_2 AAR-evoked ERK activation appears to be slower in arrestin deficient cells than that in WT cells, especially when cells are restimulated after a 5-min stimulation and a 30-min wash (a protocol that allows monitoring resensitization) [50;71]. These findings suggest that arrestin plays a role in acceleration of α_2 AR-mediated ERK signaling, presumably through mediating endocytosis which leads to recycling and replenishment of the surface α_2 AAR pool for agonist activation. Similarly, arrestin-mediated endocytosis has been previously suggested as a prerequisite for β_2 AR resensitization [72].

Arrestin also is critical in defining the spatial profiles of α_2 AR-evoked ERK activation. In WT MEFs, α_2 AAR-evoked ERK phosphorylation is first detected in cytosol (2 min) and then translocated into nuclei at later time points (10 min). However, in the absence of arrestin, α_2 AAR-evoked ERK phosphorylation is enriched in the nuclei of target cells from the earliest time point (1 min) evaluated [71].

4.4. Arrestin serves as a molecular switch determining Src involvement in α_2 AR-activation of ERK

Studies done by Dr. Lefkowitz and colleagues first identified arrestin as a signaling scaffold linking β_2 AR, Src and MEK to ERK activation [73;74]. Using pharmacological inhibitor blocking and dominant negative inhibition approaches, we found that Src tyrosine kinase also is involved in endogenous α_2 AAR-mediated ERK activation, and Src involvement in this process requires the presence of arrestin [71]. Stimulation of α_2 AAR enhances the complex formation of Src and arrestin, and promotes Src activation. When arrestin is absent, the α_2 AAR is still able to elicit ERK signaling, but through a Src-independent pathway [71]. Src-dependent and -independent pathways both converge on the Ras-Raf-MEK pathway [75] to activate ERK phosphorylation [71]. Therefore, in the G protein-dependent ERK activation by α_2 AAR, arrestin serves as molecular switch, linking α_2 AAR to the Src-dependent but not to the Src-independent pathway. The receptor tyrosine kinase, EGFR, is not required for α_2 AAR-evoked ERK signaling [71], despite their reported involvement in ERK activation by many other GPCRs [74].

5. Regulation of the α_2 AR by the multi-domain protein, spinophilin

Spinophilin (also known as Neurabin II) is a ubiquitous protein named for its enrichment in dendritic spines [76]. Spinophilin has multiple domains including an actin-binding domain, protein phosphatase 1 (PP1)-binding and regulatory domain, a PSD-95/Discs large/ZO-1 homology (PDZ) domain, and three coiled-coil domains. In the nervous system, spinophilin

targets PP1 to ionotropic glutamate receptors, thus modulating synaptic plasticity [77;78]. Through its interaction with F-actin, spinophilin also has been implicated in spine morphogenesis [77;79] and neuronal migration [80;81]. Studies by Smith *et al.* [82] and Richman *et al.* [43] demonstrated that the sequence region encompassed by spinophilin amino acids 151–444 (Sp151–444) interacts with GPCRs, specifically the G_i/G_o -coupled D2 dopamine receptor [82] and all three α_2 AR subtypes [43], *via* their 3i loops. More recently, interaction of spinophilin with the 3i loop of α_1 AR also has been reported [83]. In contrast, neurabin I, which is highly homologous to neurabin II/spinophilin except in the “GPCR binding domain”, does not interact in a detectable fashion with these GPCRs [43;84].

5.1. Spinophilin tethers the α_2 AR at the cell surface

In renal epithelial cells (including MDCKII cells), endogenous spinophilin is enriched at the basolateral surface, where the α_2 AR subtypes localize [79]. Taking advantage of the unique targeting property of the α_{2B} AR subtype in polarized MDCK cells (random delivery to both apical and basolateral surfaces with rapid turnover at the apical surface), Brady *et al.* found that redirection of the receptor binding domain of spinophilin to the apical surface significantly extends the half life of α_{2B} AR at this surface compartment [85], consistent with the interpretation that endogenous spinophilin is responsible for, at least in part, surface retention of the α_2 AR at the basolateral surface. Moreover, in MEFs without spinophilin expression (derived from Sp^{-/-} mouse embryos), turnover of the α_{2B} AR from the cell surface following agonist treatment is much accelerated and occurs to a larger extent than that in WT cells expressing spinophilin [85]. Since spinophilin and arrestin both interact with the α_2 AR 3i loop and are mutually exclusive for this interaction, the accelerated internalization of the α_2 AR is presumably due to unimpeded arrestin binding to the receptor in the absence of spinophilin, which leads to receptor endocytosis.

5.2. Spinophilin competes for agonist-induced GRK2 binding to the α_2 AR- $G_{\beta\gamma}$ complex

Spinophilin interaction with the α_{2A} AR requires the N- and C- terminal ends of the 3i loop of the receptor, which form amphipathic helices predicted to lie just beneath surface membrane [46]. These helices also have been implicated in receptor-G protein coupling. However, spinophilin binding seems not to perturb α_2 AR-G protein coupling (Wang and Limbird, unpublished finding). Thus spinophilin likely recognizes the α_2 AR-G protein complex. In support of this hypothesis, we found that agonist-enhanced interaction of spinophilin with the α_2 AR is diminished when cells are pretreated with pertussis toxin or expressing GRK2-C terminus [50], both conditions which impair functional interaction between GPCR and the $G_{i/o}$ subfamily of G proteins and block $G_{\beta\gamma}$ -mediated signal transduction. Thus, spinophilin interaction with the α_2 AR seems to require α_2 AR- $G_{\beta\gamma}$ interactions and/or G protein-mediated signaling events. Whether or not spinophilin directly interacts with the $\beta\gamma$ subunits of G proteins has not yet been established.

The N- and C- terminal proximal regions of the α_2 AR 3i loop that interact with spinophilin [46] are also involved in GRK2 binding [28], raising the possibility of competition between spinophilin and GRK2 for the agonist-occupied receptor. Indeed, agonist-induced GRK2 association with the α_2 AR is prevented when spinophilin is overexpressed in the same cell background [50]. However, under this circumstance the amount of GRK2 translocated to the cell membrane following agonist treatment is not perturbed [50], indicating that spinophilin blocks binding to receptor- $\beta\gamma$ interactions but does not perturb GRK2 translocation.

5.3. Spinophilin attenuates α_2 AR phosphorylation

Spinophilin competes for α_2 AR interaction with GRK2 and arrestin, which are responsible for catalyzing and stabilizing α_2 AR phosphorylation, respectively. Therefore, association of spinophilin with the α_2 AR leads to alteration of α_2 AR phosphorylation following agonist stimulation. In MEFs without spinophilin expression (where arrestin action is unopposed), agonist stimulation causes a significant increase in agonist-elicited phosphorylation of the α_2 AR as compared to that in WT cells [50]. On the other hand, overexpression of spinophilin in cells significantly attenuates agonist-induced α_2 AR phosphorylation [86]. Intriguingly, this spinophilin effect requires the presence of arrestin to be detected, since in cells with low levels of endogenous arrestin expression, such as COS M6 cells, the effect of spinophilin on α_2 AR phosphorylation is negligible unless arrestin is heterologously expressed in these cells (which stabilizes the α_2 AR phosphorylation) [50]. These findings suggest that spinophilin principally functions as an antagonist of arrestin actions, or as “arrestin’s nemesis”.

5.4. Spinophilin regulates α_2 AR signaling duration and response sensitivity

Arrestin association with the α_2 AR results in desensitization as well as acceleration of α_2 AR-mediated ERK signaling. Through competing for GRK and arrestin association with the α_2 AR, spinophilin counteracts these arrestin-mediated functions. In spinophilin-deficient MEFs, ERK activation by endogenously expressed α_{2A} AR desensitizes significantly faster than that in WT MEFs [50]. Also, the rate of α_{2A} AR-mediated ERK is more rapid in $Sp^{-/-}$ cells than in WT cells, especially when cells are restimulated after a 5-min stimulation and a 30-min wash (representing resensitization) [50]. Using combined gene knockout and RNA silencing strategies, we confirmed that both desensitization and acceleration of α_{2A} AR-mediated ERK signaling in $Sp^{-/-}$ cells depends on the presence of arrestin [50]. As discussed earlier, arrestin-dependent acceleration of ERK stimulation is conceivably due to recycling of α_{2A} AR to the surface following arrestin-dependent endocytosis, increasing the receptor population available for reactivation. Consistent with this hypothesis, blockade of clathrin-coated pit-mediated α_{2A} AR internalization by incubation of MEFs in K^+ -depleted medium (low $[K^+]_o$) eliminates the accelerated rate of α_{2A} AR-mediated ERK activation seen in $Sp^{-/-}$ cells when compared to WT MEFs. Taken together, through antagonizing arrestin functions, spinophilin regulates both α_2 AR signaling duration and response sensitivity.

5.5. Other potential functions of spinophilin

Spinophilin contains multiple domains. However, the receptor binding domain of spinophilin alone seems to be sufficient to compete for arrestin binding to the α_2 AR [86]. How the other domains of spinophilin may contribute to antagonism of arrestin functions and/or link the receptor to signaling and regulatory pathways has not been rigorously explored. The PP1 binding domain of spinophilin may recruit PP1 to regulate the phosphorylation level of the α_2 AR, thus affecting the interaction equilibrium between spinophilin and arrestin with the receptor [46]. The PDZ domain of spinophilin has been shown to interact with C-terminal end of the p70^{S6} kinase (p70^{S6K}) [87;88]. Stimulation of α_{2A} AR can result in activation of p70^{S6K} [86]. Therefore, spinophilin may serve as a scaffold linking the α_{2A} AR to the p70^{S6K} signaling pathway.

By analogy to arrestin enrichment at the cell surface following stimulation of GPCRs, α_2 AR activation also leads to enrichment of spinophilin at the surface [89]. This phenomenon requires the actin-binding domain of spinophilin and appears to involve G protein-mediated signaling pathways, since it can be eliminated by pertussis toxin treatment of target cells [89]. Intriguingly, only agonist activation of the α_{2A} but not the α_{2B} AR subtype can cause this effect in a detectable fashion, despite the fact that both subtypes interact with spinophilin [89]. This

subtype-selective enrichment of spinophilin may represent a mechanism contributing to subtype signaling diversity between the α_{2A} and the α_{2B} AR, which may serve as a base for different physiological functions elicited by these two subtypes [90].

6. *In vivo* relevance of the reciprocal regulation of α_2 AR by spinophilin and arrestin

We have identified spinophilin antagonism of multiple arrestin functions in regulating the α_2 AR [50]. Figure 2 provides a schematic diagram of the reciprocal regulation of α_2 AR by spinophilin and arrestin. Spinophilin interaction with α_2 ARs is enhanced by agonist occupancy but diminished by GRK2-catalyzed receptor phosphorylation. This is qualitatively different from arrestin interactions with α_2 AR, which are enhanced by phosphorylation of the receptor [55;91]. The ability of spinophilin to compete for GRK2 binding to the agonist- α_2 AR- $G_{\beta\gamma}$ complex, thus blocking receptor phosphorylation and enhanced arrestin binding, may be the sole mechanism by which spinophilin antagonizes arrestin functions. However, we cannot rule out direct competition for arrestin binding by spinophilin, albeit diminished by α_2 AR phosphorylation [46]. Regardless of whether either or both of these mechanisms dominate in intact cells, it is clear that spinophilin serves as a functional antagonist of the multiple functions of arrestin in receptor signaling and trafficking.

The data shown in Fig. 3 suggest that our *in vitro* findings indicating reciprocal regulation of α_2 AR functions by spinophilin and arrestin have *in vivo* relevance. UK 14,304, an α_2 -agonist, evokes sedation in WT mice *via* activation of the α_{2A} AR subtype [5]. In $Sp^{-/-}$ mice, α_2 -agonists become more efficacious, manifest by a leftward shift in the UK 14,304 dose response curve for sedation (Fig. 3, left panel). In contrast, $Arr3^{-/-}$ mice are more resistant to UK 14,304-evoked sedation, manifest by a rightward shift in the dose response curve (Fig. 3, right panel). Despite the unknown mechanism of α_{2A} AR elicited sedation, these *in vivo* data strongly suggest that spinophilin antagonism for arrestin functions in regulating α_{2A} AR exist in *native* target cells.

7. Conclusion

Interactions of the α_2 AR with various surface and cytoplasmic proteins would represent an important mechanism regulating α_2 AR-elicited physiological and pharmacological functions in response to different ligands, in different cell types and under different disease conditions. While heterologous systems are powerful in studying α_2 AR interaction with other proteins, the ultimate goal is to identify the functional relevance of such interaction in native cells. Identification of more interactors of the α_2 AR and understanding of functional roles of the observed association would eventually provide therapeutic insights on manipulating α_2 AR function in a variety of clinical settings, such as hypertension, pain diminution, attentional focus (as in attention deficit and hyperactivity disorder) and cognition enhancement.

Acknowledgements

Q.W. is supported by an American Heart Association Scientist Development grant. L.E.L. is supported by National Institutes of Health Grants HL43671 and DK43879.

References

1. Wilson MH, Puranam RS, Ottman R, Gilliam C, Limbird LE, George AL Jr, McNamara JO. Evaluation of the alpha(2A)-adrenergic receptor gene in a heritable form of temporal lobe epilepsy. *Neurology* 1998;51:1730–1731. [PubMed: 9855534]

2. Schramm NL, McDonald MP, Limbird LE. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. *J Neurosci* 2001;21:4875–4882. [PubMed: 11425914]
3. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. *Science* 1996;273:801–3. [PubMed: 8670421]
4. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, Kobilka BK, Hein L. Abnormal regulation of the sympathetic nervous system in alpha2A- adrenergic receptor knockout mice. *Mol Pharmacol* 1999;56:154–161. [PubMed: 10385696]
5. Lakhani PP, MacMillan LB, Guo TZ, McCool BA, Lovinger DM, Maze M, Limbird LE. Substitution of a mutant alpha2a-adrenergic receptor via “hit and run”; gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. *Proc Natl Acad Sci U S A* 1997;94:9950–5. [PubMed: 9275232]
6. Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. *J Neurosci* 1997;17:7157–7165. [PubMed: 9278550]
7. Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. *J Neurosci* 2002;22:8771–8777. [PubMed: 12351753]
8. Ma D, Zerangue N, Lin YF, Collins A, Yu M, Jan YN, Jan LY. Role of ER export signals in controlling surface potassium channel numbers. *Science* 2001;291:316–9. [PubMed: 11209084]
9. Marrs W, Kuperman J, Avedian T, Roth RH, Jentsch JD. Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. *Neuropsychopharmacology* 2005;30:1500–1510. [PubMed: 15714223]
10. Limbird LE. Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. *FASEB J* 1988;2:2686–2695. [PubMed: 2840317]
11. Kobilka B. Adrenergic receptors as models for G protein-coupled receptors. *Annu Rev Neurosci* 1992;15:87–114. [PubMed: 1575451]
12. Richman JG, Regan JW. Alpha 2-adrenergic receptors increase cell migration and decrease F- actin labeling in rat aortic smooth muscle cells. *Am J Physiol* 1998;274:C654–C662. [PubMed: 9530096]
13. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. *EMBO Rep* 2004;5:30–34. [PubMed: 14710183]
14. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. *Mol Pharmacol* 2004;66:1–7. [PubMed: 15213289]
15. Nobles M, Benians A, Tinker A. Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. *Proc Natl Acad Sci U S A* 2005;102:18706–18711. [PubMed: 16352729]
16. Small KM, Schwarb MR, Glinka C, Theiss CT, Brown KM, Seman CA, Liggett SB. Alpha2A- and alpha2C-adrenergic receptors form homo- and heterodimers: the heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment. *Biochemistry* 2006;45:4760–4767. [PubMed: 16605244]
17. Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. *J Biol Chem* 2003;278:10770–10777. [PubMed: 12529373]
18. Prinster SC, Holmqvist TG, Hall RA. Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. *J Pharmacol Exp Ther* 2006;318:974–981. [PubMed: 16757535]
19. Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. *Mol Pharmacol* 2003;64:1317–1324. [PubMed: 14645661]
20. Zhang YQ, Limbird LE. Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. *Biochem Soc Trans* 2004;32:856–860. [PubMed: 15494033]
21. Rios C, Gomes I, Devi LA. Interactions between delta opioid receptors and alpha-adrenoceptors. *Clin Exp Pharmacol Physiol* 2004;31:833–836. [PubMed: 15566403]
22. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. *Annu Rev Biochem* 1998;67:653–92. [PubMed: 9759500]

23. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. *Annu Rev Neurosci* 2004;27:107–144. [PubMed: 15217328]
24. Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. *Annu Rev Pharmacol Toxicol* 1998;38:289–319. [PubMed: 9597157]
25. Eason MG, Moreira SP, Liggett SB. Four consecutive serines in the third intracellular loop are the sites for beta-adrenergic receptor kinase-mediated phosphorylation and desensitization of the alpha 2A-adrenergic receptor. *J Biol Chem* 1995;270:4681–4688. [PubMed: 7876239]
26. Jewell-Motz EA, Liggett SB. An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization. *Biochemistry* 1995;34:11946–11953. [PubMed: 7547931]
27. Jewell-Motz EA, Small KM, Theiss CT, Liggett SB. Alpha 2A/alpha 2C-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation. *J Biol Chem* 2000;275:28989–93. [PubMed: 10893245]
28. Pao CS, Benovic JL. Structure/function analysis of alpha2A-adrenergic receptor interaction with G protein-coupled receptor kinase 2. *J Biol Chem* 2005;280:11052–11058. [PubMed: 15653687]
29. Liang M, Eason MG, Jewell-Motz EA, Williams MA, Theiss CT, Dorn GW, Liggett SB. Phosphorylation and functional desensitization of the alpha2A-adrenergic receptor by protein kinase C. *Mol Pharmacol* 1998;54:44–49. [PubMed: 9658188]
30. Zhu Q, Qi LJ, Shi A, bou-Samra A, Deth RC. Protein kinase C regulates alpha(2A/D)-adrenoceptor constitutive activity. *Pharmacology* 2004;71:80–90. [PubMed: 15118347]
31. Liang M, Freedman NJ, Theiss CT, Liggett SB. Serine 232 of the alpha(2A)-adrenergic receptor is a protein kinase C-sensitive effector coupling switch. *Biochemistry* 2001;40:15031–15037. [PubMed: 11732925]
32. Liang M, Eason MG, Theiss CT, Liggett SB. Phosphorylation of Ser360 in the third intracellular loop of the alpha2A-adrenoceptor during protein kinase C-mediated desensitization. *Eur J Pharmacol* 2002;437:41–46. [PubMed: 11864637]
33. Eason MG, Jacinto MT, Theiss CT, Liggett SB. The palmitoylated cysteine of the cytoplasmic tail of alpha 2A- adrenergic receptors confers subtype-specific agonist-promoted downregulation. *Proc Natl Acad Sci U S A* 1994;91:11178–11182. [PubMed: 7972030]
34. Klein U, Ramirez MT, Kobilka BK, von ZM. A novel interaction between adrenergic receptors and the alpha-subunit of eukaryotic initiation factor 2B. *J Biol Chem* 1997;272:19099–19102. [PubMed: 9235896]
35. Weber B, Schaper C, Scholz J, Bein B, Rodde C, Tonner H. Interaction of the amyloid precursor like protein 1 with the alpha(2A)-adrenergic receptor increases agonist-mediated inhibition of adenylate cyclase. *Cell Signal*. 2006
36. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 2001;81:741–766. [PubMed: 11274343]
37. Keefer JR, Limbird LE. The alpha 2A-adrenergic receptor is targeted directly to the basolateral membrane domain of Madin-Darby canine kidney cells independent of coupling to pertussis toxin-sensitive GTP-binding proteins. *J Biol Chem* 1993;268:11340–11347. [PubMed: 8388390]
38. Wozniak M, Limbird LE. The three alpha 2-adrenergic receptor subtypes achieve basolateral localization in Madin-Darby canine kidney II cells via different targeting mechanisms. *J Biol Chem* 1996;271:5017–5024. [PubMed: 8617778]
39. Keefer JR, Kennedy ME, Limbird LE. Unique structural features important for stabilization versus polarization of the alpha 2A-adrenergic receptor on the basolateral membrane of Madin-Darby canine kidney cells. *J Biol Chem* 1994;269:16425–16432. [PubMed: 8206950]
40. Saunders C, Limbird LE. Microtubule-dependent regulation of alpha(2B) adrenergic receptors in polarized MDCKII cells requires the third intracellular loop but not G protein coupling. *Mol Pharmacol* 2000;57:44–52. [PubMed: 10617677]
41. Edwards SW, Limbird LE. Role for the third intracellular loop in cell surface stabilization of the alpha2A-adrenergic receptor. *J Biol Chem* 1999;274:16331–6. [PubMed: 10347190]

42. Prezeau L, Richman JG, Edwards SW, Limbird LE. The zeta isoform of 14-3-3 proteins interacts with the third intracellular loop of different alpha2-adrenergic receptor subtypes. *J Biol Chem* 1999;274:13462–13469. [PubMed: 10224112]
43. Richman JG, Brady AE, Wang Q, Hensel JL, Colbran RJ, Limbird LE. Agonist-regulated Interaction between alpha 2-Adrenergic Receptors and Spinophilin. *J Biol Chem* 2001;276:15003–8. [PubMed: 11154706]
44. Wu G, Krupnick JG, Benovic JL, Lanier SM. Interaction of arrestins with intracellular domains of muscarinic and alpha2-adrenergic receptors. *J Biol Chem* 1997;272:17836–42. [PubMed: 9211939]
45. DeGraff JL, Gurevich VV, Benovic JL. The third intracellular loop of alpha 2-adrenergic receptors determines subtype specificity of arrestin interaction. *J Biol Chem* 2002;277:43247–43252. [PubMed: 12205092]
46. Wang Q, Limbird LE. Regulated Interactions of the alpha 2A Adrenergic Receptor with Spinophilin, 14-3-3zeta, and Arrestin 3. *J Biol Chem* 2002;277:50589–50596. [PubMed: 12376539]
47. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. *Cell* 1996;84:889–897. [PubMed: 8601312]
48. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ, Cantley LC. The structural basis for 14-3-3:phosphopeptide binding specificity. *Cell* 1997;91:961–971. [PubMed: 9428519]
49. Alblas J, van Corven EJ, Hordijk PL, Milligan G, Moolenaar WH. Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts. *J Biol Chem* 1993;268:22235–22238. [PubMed: 8226727]
50. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, Greengard P, Limbird LE. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. *Science* 2004;304:1940–1944. [PubMed: 15218143]
51. Pfister C, Chabre M, Plouet J, Tuyen VV, De Kozak Y, Faure JP, Kuhn H. Retinal S antigen identified as the 48K protein regulating light-dependent phosphodiesterase in rods. *Science* 1985;228:891–893. [PubMed: 2988124]
52. Wilden U, Hall SW, Kuhn H. Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. *Proc Natl Acad Sci U S A* 1986;83:1174–1178. [PubMed: 3006038]
53. Sitaramayya A, Liebman PA. Phosphorylation of rhodopsin and quenching of cyclic GMP phosphodiesterase activation by ATP at weak bleaches. *J Biol Chem* 1983;258:12106–12109. [PubMed: 6313637]
54. Palczewski K, McDowell JH, Hargrave PA. Purification and characterization of rhodopsin kinase. *J Biol Chem* 1988;263:14067–14073. [PubMed: 2844754]
55. Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. *Trends Cell Biol* 2002;12:130–138. [PubMed: 11859025]
56. Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. *Proc Natl Acad Sci U S A* 1986;83:2797–2801. [PubMed: 2871555]
57. Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH, Benovic JL. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. *Nature* 1996;383:447–450. [PubMed: 8837779]
58. Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, Barak LS. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. *Proc Natl Acad Sci U S A* 1999;96:3712–3717. [PubMed: 10097102]
59. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. Activation and targeting of extracellular signal-regulated kinases by beta -arrestin scaffolds. *Proc Natl Acad Sci U S A* 2001;98:2449–2454. [PubMed: 11226259]
60. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. *Science* 2000;290:1574–1577. [PubMed: 11090355]

61. Benovic JL, Kuhn H, Weyand I, Codina J, Caron MG, Lefkowitz RJ. Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). *Proc Natl Acad Sci U S A* 1987;84:8879–8882. [PubMed: 2827157]
62. Byk T, Bar-Yaacov M, Doza YN, Minke B, Selinger Z. Regulatory arrestin cycle secures the fidelity and maintenance of the fly photoreceptor cell. *Proc Natl Acad Sci U S A* 1993;90:1907–1911. [PubMed: 8446607]
63. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. *J Biol Chem* 1999;274:32248–57. [PubMed: 10542263]
64. Alloway PG, Howard L, Dolph PJ. The formation of stable rhodopsin-arrestin complexes induces apoptosis and photoreceptor cell degeneration. *Neuron* 2000;28:129–138. [PubMed: 11086989]
65. Kiselev A, Socolich M, Vinos J, Hardy RW, Zuker CS, Ranganathan R. A molecular pathway for light-dependent photoreceptor apoptosis in *Drosophila*. *Neuron* 2000;28:139–152. [PubMed: 11086990]
66. Daunt DA, Hurt C, Hein L, Kallio J, Feng F, Kobilka BK. Subtype-specific intracellular trafficking of alpha2-adrenergic receptors. *Mol Pharmacol* 1997;51:711–720. [PubMed: 9145909]
67. Schramm NL, Limbird LE. Stimulation of mitogen-activated protein kinase by G protein-coupled alpha(2)-adrenergic receptors does not require agonist-elicited endocytosis. *J Biol Chem* 1999;274:24935–24940. [PubMed: 10455169]
68. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. *J Biol Chem* 2000;275:17201–10. [PubMed: 10748214]
69. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent {beta}-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. *Proc Natl Acad Sci U S A* 2003;10782–10787. [PubMed: 12949261]
70. Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ, Luttrell LM. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. *J Biol Chem* 2002;277:9429–9436. [PubMed: 11777902]
71. Wang Q, Lu R, Zhao J, Limbird LE. Arrestin serves as a molecular switch, linking endogenous alpha 2-adrenergic receptor to SRC-dependent but not SRC-independent ERK activation. *J Biol Chem*. 2006
72. Zhang J, Barak LS, Winkler KE, Caron MG, Ferguson SS. A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types. *J Biol Chem* 1997;272:27005–27014. [PubMed: 9341139]
73. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, la Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. *Science* 1999;283:655–661. [PubMed: 9924018]
74. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. *Oncogene* 2001;20:1532–1539. [PubMed: 11313899]
75. Hawes BE, van BT, Koch WJ, Luttrell LM, Lefkowitz RJ. Distinct pathways of Gi- and Gq-mediated mitogen-activated protein kinase activation. *J Biol Chem* 1995;270:17148–17153. [PubMed: 7615510]
76. Allen PB, Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. *Proc Natl Acad Sci U S A* 1997;94:9956–61. [PubMed: 9275233]
77. Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, Zhuo M, Allen PB, Ouimet CC, Greengard P. Spinophilin regulates the formation and function of dendritic spines. *Proc Natl Acad Sci U S A* 2000;97:9287–92. [PubMed: 10922077]
78. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC, Greengard P. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. *Nat Neurosci* 1999;2:13–7. [PubMed: 10195174]

79. Satoh A, Nakanishi H, Obaishi H, Wada M, Takahashi K, Satoh K, Hirao K, Nishioka H, Hata Y, Mizoguchi A, Takai Y. Neurabin-II/spinophilin. An actin filament-binding protein with one pdz domain localized at cadherin-based cell-cell adhesion sites. *J Biol Chem* 1998;273:3470–5. [PubMed: 9452470]
80. Tsukada M, Prokscha A, Ungewickell E, Eichele G. Doublecortin association with actin filaments is regulated by neurabin II. *J Biol Chem* 2005;280:11361–11368. [PubMed: 15632197]
81. Tsukada M, Prokscha A, Eichele G. Neurabin II mediates doublecortin-dephosphorylation on actin filaments. *Biochem Biophys Res Commun* 2006;343:839–847. [PubMed: 16564023]
82. Smith FD, Oxford GS, Milgram SL. Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. *J Biol Chem* 1999;274:19894–900. [PubMed: 10391935]
83. Wang X, Zeng W, Soyombo AA, Tang W, Ross EM, Barnes AP, Milgram SL, Penninger JM, Allen PB, Greengard P, Muallem S. Spinophilin regulates Ca²⁺ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. *Nat Cell Biol* 2005;7:405–411. [PubMed: 15793568]
84. MacMillan LB, Bass MA, Cheng N, Howard EF, Tamura M, Strack S, Wadzinski BE, Colbran RJ. Brain actin-associated protein phosphatase 1 holoenzymes containing spinophilin, neurabin, and selected catalytic subunit isoforms. *J Biol Chem* 1999;274:35845–54. [PubMed: 10585469]
85. Brady AE, Wang Q, Colbran RJ, Allen PB, Greengard P, Limbird LE. Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic receptors. *J Biol Chem* 2003;278:32405–32412. [PubMed: 12738775]
86. Wang, Q.; Limbird, LE. Unpublished findings. 2006.
87. Buchsbaum RJ, Connolly BA, Feig LA. Regulation of p70 S6 kinase by complex formation between the Rac guanine nucleotide exchange factor (Rac-GEF) Tiam1 and the scaffold spinophilin. *J Biol Chem* 2003;278:18833–18841. [PubMed: 12531897]
88. Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Sabatini DM, Snyder SH. Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. *Proc Natl Acad Sci U S A* 1998;95:8351–8356. [PubMed: 9653190]
89. Brady AE, Wang Q, Allen PB, Rizzo M, Greengard P, Limbird LE. Alpha 2-adrenergic agonist enrichment of spinophilin at the cell surface involves beta gamma subunits of Gi proteins and is preferentially induced by the alpha 2A-subtype. *Mol Pharmacol* 2005;67:1690–1696. [PubMed: 15705742]
90. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. *Am J Physiol Regul Integr Comp Physiol* 2002;283:R287–R295. [PubMed: 12121839]
91. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. *Biochem J*. Sept 8;Epub ahead of print: 2003

Abbreviations

GPCR	G protein-coupled receptor
α₂AR	α ₂ -adrenergic receptor
RGS	regulatory of G protein signaling
MAPK	mitogen-activated protein kinase
GRK	G protein-coupled receptor kinase

eIF	eukaryotic translation initiation factor
APLP	amyloid precursor like protein
APP	amyloid precursor protein
ERK	extracellular signal-regulated kinase
JNK	c-Jun amino-terminal kinase
MEF	mouse embryonic fibroblast
PP1	protein phosphatase 1
PDZ	PSD-95/Discs large/ZO-1 homology

Figure 1. Postulated regulatory cycle for interactions of spinophilin, 14-3-3 ζ and arrestin 3 with the 3i loop of the α_2 AR

The interactions of the α_2 AR with 14-3-3 ζ likely occur when the receptor is in an agonist naïve state; these interactions might contribute to receptor targeting and retention at the cell surface, but the functional role of α_2 AR-14-3-3 ζ interactions has not been established. Agonist occupancy can stabilize the α_2 AR interaction with arrestin as well as with spinophilin, depending on the phosphorylation state of the receptor. Arrestin preferentially binds to GRK-phosphorylated α_2 AR, whereas spinophilin prefers to bind to the non-phosphorylated receptor. Spinophilin and arrestin compete for interaction with the α_2 AR 3i loop.

Figure 2. Model of α_2 AR interactions with arrestin, and spinophilin, and their functional consequences

GRK2 interacts with the α_2 AR- $G_{\beta\gamma}$ complex and mediates α_2 AR phosphorylation. Spinophilin, which also recognizes the α_2 AR- $G_{\beta\gamma}$ complex and shares the interacting sites on the 3i loop with GRK2, competes for GRK2 association with the α_2 AR. GRK2-catalyzed phosphorylation of the α_2 AR is stabilized by arrestin 3 binding to the receptor, and is diminished by increasing the relative concentration of spinophilin compared to arrestin in target cells. Arrestin binding to the α_2 AR induces desensitization by disrupting coupling to G proteins and mediates endocytosis by facilitating binding to the clathrin-coated pit machinery. One outcome of α_2 AR endocytosis is receptor recycling, which may facilitate signaling activation and resensitization through replenishment of surface α_2 AR available for activation. These arrestin-mediated functions are antagonized by spinophilin interaction with the α_2 AR.

(From *Science* 304:1940)

Figure 3. Reciprocal effects of spinophilin and arrestin 3 on α_2 AR-mediated sedation *in vivo*
Sedation in response to α_2 AR-agonists was assessed *via* rotarod latency following administration of increasing doses of the α_2 -agonist UK 14,304. The EC_{50} values for sedation in $Arr3^{-/-}$ and corresponding WT litter mates (n=5 for each genotype) are 2.1 and 1.1 mg/kg, respectively, and the EC_{50} values for sedation in $Sp^{-/-}$ and corresponding WT mice (n=6 for dose 0.56 mg/kg and n=11 for the rest doses for each genotype) are 0.4 and 1.2 mg/kg, respectively. *, $p < 0.01$; **, $p < 0.05$.

Table 1

 α_2 AR-interacting proteins

Interacting protein(s)	α_2 AR subtype(s)	Functional role(s) implicated	Reference(s)
GPCR dimerization			
<i>Homo-dimerization</i>			
	α_{2A}	Precoupled to G proteins	[15]
<i>Hetero-dimerization</i>			
α_{2C} AR	α_{2A}	Attenuating agonist-induced α_{2A} AR phosphorylation, reducing arrestin binding to the α_{2A} AR	[16]
β_1 AR	α_{2A}	Altering ligand binding properties of β_1 AR, leading to internalization of β_1 AR in response to α_2 -agonist	[17]
β_2 AR	α_{2C}	Enhancing surface expression and internalization of α_{2C} AR, enhancing ERK activation by α_{2C} AR	[18]
μ OR	α_{2A}	Enhancing morphine-induced GTP γ S binding and ERK activation; however, no transactivation of G proteins, no interdependent internalization	[19,20]
δ OR	α_{2A}	Enhancing δ OR-mediated neurite outgrowth	[21]
Kinases			
GRK2	α_{2A} , α_{2B}	Mediating agonist-induced phosphorylation and homologous desensitization	[26,27], [29]
PKC	α_{2A}	Mediating heterologous desensitization; affecting constitutive activity of α_{2A} AR	[30–33]
Proteins interacting with the C-tail of α_2AR			
eIF-2B	α_{2A} , α_{2B} , α_{2C}	Function unknown	[35]
APLP1	α_{2A} , α_{2B} , α_{2C}	Increasing α_{2A} AR-mediated inhibition of adenylyl cyclase activity	[36]
Proteins interacting with the 3i loop of α_2AR			
14-3-3 ζ	α_{2A} , α_{2B} , α_{2C}	Function unknown, competed by phosphorylated Raf peptide	[43],[47]
spinophilin	α_{2A} , α_{2B} ,	Stabilizing receptor at surface, attenuating phosphorylation, decelerating ERK signaling rate, decreasing in vivo response sensitivity	[44],[47], [51], [86]
	α_{2C}	Function unknown	[44]
arrestin 3	α_{2A} , α_{2B} ,	Stabilizing receptor phosphorylation, mediating endocytosis and desensitization, accelerating ERK signaling rate, enhancing in vivo response sensitivity	[45–47], [51]
	α_{2C}	Function unknown	[46]
arrestin 2	α_{2B}	Affinity is lower than arrestin 3	[46]